Transplant Diagnostics Market Research Report By Opportunities & Challenges in Near Future with Different Segments and Forecast 2028
The global Transplant Diagnostics market is expected to register a CAGR of 7.4% during the forecast period (2022-2028).

The report "Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product(Instrument, Reagent, Software), Application(HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User, & Region - Global Forecasts to 2028", is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period. The increasing prevalence of organ failure, the growing awareness about the importance of organ donation and transplantation, and the development of novel technologies for testing and diagnostics are some of the major factors driving the growth of the transplant diagnostics market.

Get a Sample PDF of report @

Organ transplants have gradually improved over the past 20 years and typically produce excellent results in children and young adults. However, the proportion of elderly transplant patients with comorbidities is increasing, posing a greater challenge. When compared to dialysis, renal transplants increase patient survival, and patients with liver, heart, or lung diseases that are incurable must receive life-saving transplants.

The activity of solid organ transplant programmes has been steadily increasing, but it still falls short of global needs and varies greatly between nations. Transplanting solid organs is crucial for advanced and established medical systems.

Get 10% Free Customization on this Report:

Key Market Players

The Transplant diagnostic market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key players operating in the Transplant diagnosticmarket are bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F-Hoffma-LA-Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), among others.

bioMérieux SA

bioMérieux SA (bioMérieux) is a provider of diagnostic solutions for medical and industrial applications. These products are used to diagnose cardiovascular diseases, targeted cancers, and infectious diseases. The company also provides various in vitro diagnostic solutions to hospitals.

Thermo Fisher Scientific

Thermo Fisher Scientific is engaged in the development, manufacturing, and marketing of analytical instruments, reagents & consumables, equipment, and software products. The company operates its businesses through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. The microbiology business under the company’s Specialty Diagnostics segment offers dehydrated and prepared culture media, collection and transport systems, microbiology instrumentation, and consumables to detect pathogens in blood, diagnostic, and rapid direct specimen tests, quality-control products, and associated products for microbiology laboratories.

Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is engaged in the development, manufacture, and marketing of medical devices, instrument systems, and reagents. BD operates through three business segments—BD Medical, BD Life Sciences, and BD Interventional. The Life Sciences division is further divided into Diagnostic Systems, Preanalytical Systems, and Biosciences sub-divisions. The company offers transplant diagnostic products under the Diagnostic Systems segment of its Life Sciences division. The company’s end users mainly include healthcare institutions, clinical laboratories, life science researchers, and the pharmaceutical industry, among others.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (Bio-Rad) is engaged in developing, manufacturing, and supplying life sciences and clinical diagnostic tools and services. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Sciences segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company operates in the market through the Clinical Diagnostics segment.

F.Hoffman-LA-Roche Ltd

F. Hoffmann-La Roche Ltd. (Roche) is a pharmaceutical and diagnostics company based in Switzerland. The company is engaged in the development, manufacturing, distribution, and marketing of therapeutic and diagnostic products. Roche operates through two business divisions, namely, Pharmaceuticals and Diagnostics. The Diagnostics division is further segmented into Centralized & Point of Care Solutions, Molecular Diagnostics, Tissue Diagnostics, and Diabetes Care. The company offers instruments, reagents, and software used during transplant diagnostic procedures through its Molecular Diagnostics business segment.

North America  to register major growth in the market during the forecast period

North America transplant diagnostic market is anticipated to register the highest growth over the forecast period of 2022 to 2028. North America accounted for the largest share of 45.5% of the transplant diagnostic market in 2022. This market is projected to reach USD 3.1 billion by 2028 from USD 2.0 billion in 2022, at a CAGR of 7.6% during the forecast period. North America holds 45.5% share of the total antimicrobial susceptibility testing market. The large share of North America can be attributed due to the growth in the geriatric population and the increase in infectious diseases., Asia-Pacific is expected to experience significant development.

Recent Developments:

·         In February 2023, BD received FDA approval for BD Onclarity HPV assay in the serology testing segment

·         In March 2023 BioRad received AQAC International and AFNOR approval for its iQ-Check kits.

·         Hoffmann-La Roche Ltd. unveiled Cobas Infinity edge, a cloud-based point-of-care platform that is available everywhere, in January 2022. Practitioners in the healthcare industry can manage patient data thanks to advanced technology. This has aided the business in diversifying its product offering.

Direct Purchase Transplant Diagnostics Market Research Report Now @

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.


Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441